369 related articles for article (PubMed ID: 15516246)
1. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
[TBL] [Abstract][Full Text] [Related]
2. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
Higgins RM; Kanji H; Hernon M; Harrison P; Lam FT; Kashi SH
Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
[TBL] [Abstract][Full Text] [Related]
4. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
6. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
Kyllönen LE; Salmela KT
Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
Zhang Y; Zhang XD; Wang Y
Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
[TBL] [Abstract][Full Text] [Related]
8. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
9. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
Trotter JF; Stolpman N; Wachs M; Bak T; Kugelmas M; Kam I; Everson GT
Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
[TBL] [Abstract][Full Text] [Related]
10. Neoral dose adjustment after conversion from C0 to C2 monitoring in stable renal transplant recipients: a prospective single center study.
Sandrini S; Bossini N; Setti G; Mazzucchelli C; Maiorca P; Cancarini G
J Nephrol; 2004; 17(2):284-90. PubMed ID: 15293530
[TBL] [Abstract][Full Text] [Related]
11. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
12. Suitable whole blood levels 2 hours after neoral in liver transplant patients: experiences at a single center.
Kim KH; Lee SG; Lee YJ; Park KM; Hwang S; Ahn CS; Moon DB; Ha TY; Song KW; Kim DS; Jung DH; Kim BS; Moon KM; Lee HJ; Park JI; Ryu JH
Transplant Proc; 2006 Nov; 38(9):2971-3. PubMed ID: 17112877
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
[TBL] [Abstract][Full Text] [Related]
14. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
17. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.
Cantarovich M; Barkun J; Giannetti N; Cecere R; Besner JG; Tchervenkov J
Transplant Proc; 2004 Mar; 36(2 Suppl):442S-447S. PubMed ID: 15041383
[TBL] [Abstract][Full Text] [Related]
18. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients.
Li J; Dahmen U; Beckebaum S; Cicinnati V; Valentin-Gamazo C; Frilling A; Malago M; Broelsch CE
Eur J Med Res; 2006 Apr; 11(4):139-45. PubMed ID: 16720277
[TBL] [Abstract][Full Text] [Related]
19. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
20. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients.
Ogino S; Hashikura Y; Katsuyama Y; Ikegami T; Nakazawa Y; Urata K; Terada M; Miyagawa S; Kawasaki S
Transplant Proc; 2004 Mar; 36(2 Suppl):299S-301S. PubMed ID: 15041357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
